Gene-targeted versus broad-spectrum therapies in ALS: comparative lessons and strategic outlook

Key Points

• Gene-targeted therapies may offer more precise intervention opportunities in amyotrophic lateral sclerosis.
• Broad-spectrum therapies have shown variable success, with key biomarkers influencing treatment pathways.
• Assessment of molecular pathways reveals distinct mechanisms of action between treatment types for ALS.
• Insights from this analysis may enable more effective treatment strategies to be developed in ALS management.